Trials / Completed
CompletedNCT02100852
TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)
A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of TGR-1202, a Novel PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- TG Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in combination with obinutuzumab (Gazyva) and chlorambucil in patients with chronic lymphocytic leukemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TGR-1202 + Obinutuzumab + Chlorambucil | TGR-1202: Oral dose Obinutuzumab: IV infusion Chlorambucil: Oral dose |
Timeline
- Start date
- 2014-03-12
- Primary completion
- 2017-11-01
- Completion
- 2017-11-01
- First posted
- 2014-04-01
- Last updated
- 2019-10-02
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02100852. Inclusion in this directory is not an endorsement.